Gagnon Securities LLC Actinium Pharmaceuticals, Inc. Transaction History
Gagnon Securities LLC
- $467 Million
- Q3 2025
A detailed history of Gagnon Securities LLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Gagnon Securities LLC holds 226,257 shares of ATNM stock, worth $294,134. This represents 0.08% of its overall portfolio holdings.
Number of Shares
226,257
Previous 226,622
0.16%
Holding current value
$294,134
Previous $317,000
14.2%
% of portfolio
0.08%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding ATNM
# of Institutions
64Shares Held
6.8MCall Options Held
42.3KPut Options Held
0-
Black Rock Inc. New York, NY1.88MShares$2.44 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$1.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny625KShares$812,1060.0% of portfolio
-
Acadian Asset Management LLC Boston, MA490KShares$636,4500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA328KShares$426,9440.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $32.7M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...